reveglucosidase alfa (BMN 701)
/ BioMarin
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 27, 2014
BMN701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease
(clinicaltrials.gov)
- P3; N=50; Recruiting; Sponsor: BioMarin Pharmaceutical; Initiation date: Dec 2013 ->Mar 2014
Trial initiation date • Biosimilar
1 to 1
Of
1
Go to page
1